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most widely used phenotyping system, has been opti-
mized to identify (and exclude) with highest sensitivity 
patients with CXCR4-tropic viruses in a given clinical 
specimen. This sensitivity reaches down to the detection 
of 0.3% of X4-tropic virus (version ESTA  [2–4] ). As a 
consequence, all patients with traces of X4-tropic HIV 
are excluded from therapy with a coreceptor antagonist. 
This is current practice although deep-sequencing ap-
proaches have demonstrated that low frequencies of this 
‘bad virus’ can be identified in almost any patient, irre-
spective of the stage of infection  [5] and therapy response 
 [6, 7] .
 In response to this potential shortcoming of current 
tropism determination systems, we have developed a test 
platform, the ‘XTrack system’, that combines sequence 
aspects and structural aspects in 3 elements: TrackC, 
geno2pheno [coreceptor] (a genotypic approach) and PhenX-
R: all samples are first tested with TrackC, those with 
unclear results are analyzed by geno2pheno and ambi-
guities by replicative phenotyping with PhenX-R. 
 Element 1 (TrackC) 
 This is sufficient for approximately 80% of all analy-
ses. The capillary-based resolution of the DNA-DNA hy-
bridization products between a patient-derived viral 
cDNA sequence spanning the V3 loop of the viral  env 
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 Abstract 
 XTrack, a rapid, cost-effective diagnostic HIV tropism system, 
yields predictive results and dissects virus mixtures. It is 
based on the duplexing of patient samples with selective 
DNA probes, combined with sequence-based analysis and 
replicative phenotyping for ambiguous samples. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Overall, clinical studies have demonstrated a good 
agreement between the results of phenotypic tests (Tro-
file) and genotypic prediction systems (e.g. geno2pheno) 
for the HIV tropism in the plasma of HIV-1-infected pa-
tients. Despite an overall good correlation of tropism test 
with the clinical response of patients to coreceptor an-
tagonists, several key issues still remain insufficiently an-
swered:
 In several trials, a substantial number of patients pre-
dicted to harbor a virus with nonresponsive tropism did 
show a significant clinical response to maraviroc (MVC) 
treatment  [1] . Clinically more important, Trofile, as the 
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gene with a predefined, well-characterized, labeled probe 
yields migration products that are suitable for separating 
and classifying R5-tropic and X4-tropic or not-assignable 
products. Examples are depicted in  figure 1 .
 The use of this simple technique provides answers in 
the most rapid fashion as the entire process from the 
workup of viral RNA to the analysis can be fitted into 1 
day. TrackC employs 2–3 such V3 probes, and each capil-
lary resolution requires an electrophoretic run of about 
40 min. Another advantage of this hybridization step is 
the ability to easily resolve mixed virus populations: with 
a sensitivity of 3%, additional virus species or viral mi-
norities are detected and assigned.
 We demonstrated that the XTrack system is useful for 
viral loads as low as 200 copies/ml of plasma and pos-
sesses a high technical reproducibility of  1 95%. It is also 
applicable to proviral DNA samples  [TK, unpublished] .
 Element 2 (geno2pheno [coreceptor] ) 
 We estimate that in about 20% of analyses a confirma-
tion with a second, independent method is indicated in 
order to verify the TrackC result. For this second analysis, 
the nucleic acid sequence of the env V3 region is deter-
mined and subjected to a ‘classic’ genotypic analysis us-
ing geno2pheno. In most cases, initial TrackC results can 
be reproduced; for discordant test results, an algorithm 
assists with the assignment probability.
 Element 3 (PhenX-R) 
 In rare cases, a tropism assignment can still not be 
reached with confidence by the first 2 methods since as-
pects such as length polymorphisms of the V3 loop, the 
sequence distance of noncanonical HIV variants or the 
presence of dual-tropic viruses do not permit a straight 
identification with the genotyping methods.
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 Fig. 1. Three electrophoregrams of the TrackC system for diag-
nostic tropism determination. Each shows the migration of the 
single-stranded, fluorescence-labeled V3 probe (‘ss probe’) as well 
as a molecular-weight (MW) standard of reference double-strand-
ed DNA. PM = Perfect match of the double-stranded probe. Be-
tween these references, the migration of samples as a function of 
the relatedness of the R5 probe is displayed.  a A typical R5-tropic 
virus.  b X4-tropic virus with less homology to the probe (‘hetero-
duplex’).  c Two discrete peaks (‘homoduplex’, ‘heteroduplex’) re-
flect the simultaneous occurrence of both in a patient’s sample 
with a mixed virus population. 
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 In these cases, that are estimated to be in the range of 
 ! 5% of all analyses, PhenX-R, the Swiss phenotypic test 
system is used. It is directly derived from a similar test 
system to assess viral resistance to protease inhibitors or 
reverse transcriptase inhibitors  [7] . For this assay, an ex-
tended fragment of the viral  env , spanning at least the 
V2–V5 region is amplified and faithfully inserted into a 
viral cassette plasmid lacking the precise region, where it 
complements a reference HIV-1 genome to restore a fully 
infectious virus. This replication-competent construct is 
then transfected into a fully susceptible HeLa cell line 
that expresses CD4, CCR5 and CXCR4  [8] ( fig. 2 ). 
 After 4 days and up to 4 rounds of viral replication in 
the presence of a prototypic coreceptor antagonist, e.g. 
either TAK779 (blocks CCR5) or AMD 3100 (blocks 
CXCR4), viral replication is read via the expression or 
blockade of an HIV-dependent reporter gene stably ex-
pressed in these cells. As a consequence, the viral tropism 
can be read and judged directly along with the level of 
viral replication as an indicator of viral replicative fitness. 
 The presence of a replicating virus, although it neces-
sitates a biosafety environment, makes this test very sen-
sitive and also allows the assessment of viral minorities. 
Moreover, a successive round of infection in the presence 
of the other inhibitor class precisely separates mixed vi-
rus populations from true dual-tropic strains of HIV, and 
allows the assessment of viral MVC resistance. This latter 
aspect has not yet been seen to be clinically relevant, but 
may become an important factor once coreceptor antago-
nists come into wider use for patients. 
 Test Performance 
 In a parallel analysis of clinical samples from Switzer-
land and Germany, each without access to the other’s re-
sults, the performance of the respective elements of this 
Swiss HIV tropism test system was assessed:
 Reportable (for samples claimed to possess  6 1,000 cop-
ies/ml), n = 70: 
 TrackC alone: 85%, TrackC + geno2pheno: 98%, 
Trofile (ESTA): 68%.
 geno2pheno is described in another section of this 
publication, and the Trofile (ESTA) test is the published 
and clinically validated version of the Monogram pheno-
typic system. ‘ESTA’ stands for ‘enhanced sensitivity tro-
pism assay’ and is based on the modification of Trofile, 
with which less than 0.3% CXCR4-tropic viruses in a 
sample will be detected. The diagnostic service for Trofile 
is only available through their Californian laboratory.
 Ongoing studies follow the analysis of proviral DNA, 
which will open the application for special indications for 
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 Fig. 2. PhenX-R is a recombinant, trans-
fection-based phenotyping system. Pa-
tient-derived PCR products of the viral 
env are position-precisely inserted into a 
full-length clone of HIV, thereby reconsti-
tuting a replicating viral genome (green 
circle = Env). Upon DNA transfection into 
susceptible HeLa cells (with blue lining), 
the virus multiplies and produces infec-
tious virions (yellow particles). Viruses are 
used for the subsequent infection of re-
porter cells (HeLa SXR5, with brown lin-
ing), which express both CXCR4 and 
CCR5 coreceptors and possess an LTR-de-
pendent lacZ gene. In the absence of drugs 
(upper path) a quantifiable signal correlat-
ing with the level of virus expression is 
produced, independently of the viral tro-
pism. In parallel, the same procedure is 
performed in the presence of a drug, e.g. 
MVC. In this case, the quantifiable signal 
correlates with expression of X4 viruses or 
R5 viruses resistant to MVC (bottom 
path). Otherwise the signal remains com-
pletely suppressed (path in center). 
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patients with no detectable circulating HIV and also to 
lower virus loads.
 The Swiss system versus Trofile (ESTA), n = 150:
 (for standardization purposes this assessment as-
sumes all Trofile results as ‘true’)
 Sensitivity: 
 TrackC alone: 76.2%, TrackC + geno2pheno: 85.7%, 
TrackC + geno2pheno + PhenX-R: 98%.
 Specificity: 
 TrackC alone: 68.6%, TrackC + geno2pheno: 94.3%, 
TrackC + geno2pheno + PhenX-R: 98%.
 In the first European Quality Assessment panel  [9, 10] , 
the Swiss system was found to match well with the ex-
pected outcome ( fig.  3 ). In contrast to the laboratories 
which provided solely genotype-based results, the find-
ings from Basel yielded 2 discordant results (samples 3 
and 9), which, however, agree with the Trofile results. 
This may reflect the additional properties of the Swiss 
system that delivered results more in accordance with 
those from other phenotypic systems. However, it should 
be noted that the recombinant phenotypic assays could 
not detect all samples.
 Fig. 3. Compilation of the results of the 
blinded genotypic tropism testing of 12 
clonal HIV-1 variants (NRZ01-NRZ12) by 
36 dedicated laboratories (1–36). The re-
sulting HIV tropism reported by the re-
spective centers is given as an FPR value 
and colored according to the legend. The 
XTrack system is represented in lane 17. In 
the upper lanes are phenotypic results de-
termined by 3 different systems: ‘culture’ 
as MT4-culture/syncytium assay, PhenX-
R and ESTA (Trofile). 
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 The genotypic results from all the participating labo-
ratories were highly concordant. When compared to re-
combinant phenotypic assays, however, the exclusive use 
of geno2pheno seems to overestimate X4 viruses. The 
current false positive result (FPR) cutoffs for geno2pheno 
are probably too high. FPR cutoffs of 5 or 7.5% would re-
sult in R5 prediction for the samples 3 and 9 by most 
laboratories and be concordant with the Swiss and the 
phenotypic assays. Further analysis of these samples will 
follow to elucidate the underlying reasons for the differ-
ences in interpretation.
 All in all, more extensive prospective use on clinical 
specimens, along with virological and clinical outcome 
data, will serve as support in choosing the optimal system 
for the determination of the HIV tropism prior to using 
coreceptor antagonists for the treatment of HIV-infected 
patients. 
 Conclusion 
 The XTrack system, although appearing complex, 
simplifies the HIV tropism analysis by employing:
 – A quick duplex-formation assay (TrackC) to assign re-
liable tropism for the vast majority of samples ( 1 80%) 
 and to reveal mixed virus populations. 
 – The use of the sequence-based algorithm geno2pheno 
to confirm or provide further tropism information for 
samples that remained unassigned by TrackC (approx. 
15% of samples). 
 – Replicative phenotyping (PhenX-R) for functionally 
assigning the tropism or to identify dual-tropic HIV 
strains (requires a recombinant virus with sufficient 
replicative capacity). 
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